<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098422</url>
  </required_header>
  <id_info>
    <org_study_id>071960</org_study_id>
    <nct_id>NCT01098422</nct_id>
  </id_info>
  <brief_title>A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver</brief_title>
  <official_title>A Phase II Study of Yttrium-90 Radioactive Resin Microspheres in the Treatment of Colorectal Adenocarcinoma Metastatic to the Liver After Failure of First-Line Combination Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tony Reid, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sirtex Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of radioactive microsphere&#xD;
      infusion as a treatment for liver metastases from colon or rectal cancer. The investigators&#xD;
      hypothesis is that the administration of microspheres between first and second line&#xD;
      chemotherapy will increase progression-free survival time by about 2.5 months and may also&#xD;
      improve tumor response rates to subsequent second line chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, single-arm study of Yttrium-90 (Y-90) radioactive resin microspheres in&#xD;
      the treatment of colorectal adenocarcinoma metastatic to the liver in patients who have had&#xD;
      progressive disease through first line combination chemotherapy or have otherwise failed&#xD;
      first line chemotherapy due to toxicity. Expected enrollment at University of California, San&#xD;
      Diego (UCSD) is approximately 34 subjects.&#xD;
&#xD;
      The dose of Yttrium-90 radioactive resin microspheres is calculated based on body surface&#xD;
      area (to estimate normal liver volume), percentage of total liver represented by the targeted&#xD;
      lobe, and percentage of the lobe that is occupied by tumor, corrected for percentage lung&#xD;
      shunt. The prescribed dose, calculated by the nuclear medicine physician, will be delivered&#xD;
      by the interventional radiologist using the standard delivery system with frequent&#xD;
      fluoroscopic monitoring to assure ante grade blood flow immediately after treatment.&#xD;
      Additional current standard practice includes obtaining a nuclear medicine scan of the&#xD;
      patient immediately after each therapeutic Yttrium-90 microspheres administration to prove&#xD;
      delivery of the agent to the targeted portion of the liver and absence of either&#xD;
      extra-hepatic Yttrium-90 delivery or free Yttrium-90.&#xD;
&#xD;
      Blood samples will be obtained one week after the first treatment with microspheres. If the&#xD;
      patient has bi-lobar disease and the results of lab tests meet protocol specified criteria,&#xD;
      the dose will be repeated in the initially-untreated lobe. If the lab tests do not meet&#xD;
      protocol specified criteria (i.e. study inclusion/exclusion criteria), the treatment will be&#xD;
      deferred for fourteen days and labs repeated. If they are then within parameters, the patient&#xD;
      will receive the second dose. If they are not within parameters, the patient will proceed to&#xD;
      chemotherapy.&#xD;
&#xD;
      Patients will remain off chemotherapy after their final microspheres treatment for a minimum&#xD;
      of three weeks. Second line treatment options include FDA approved anti-neoplastic agents&#xD;
      used in colorectal cancer metastatic to the liver with the exception of bevacizumab and&#xD;
      capecitabine, which has been less rigorously studied with relation to Yttrium-90 radioactive&#xD;
      microspheres and therefore will not be used. When patients are found to have progressive&#xD;
      disease while receiving second line chemotherapy, they will then undergo a comprehensive&#xD;
      clinical, laboratory, and imaging assessment and enter the follow-up phase in which they are&#xD;
      assessed every five to seven months until death or withdrawal of consent.&#xD;
&#xD;
      A contrast enhanced ultrasound (CEUS) will be performed pre microsphere treatment (within 14&#xD;
      days), post microsphere treatment (2 weeks, 4 weeks, 8 weeks and 12 weeks post the&#xD;
      microsphere treatment). If patients require two treatments with microspheres, they will be&#xD;
      evaluated 2, 4, 8 and 12 weeks post the second treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Halted due to slow enrollment&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Overall Survival at 6 Months</measure>
    <time_frame>6 Months</time_frame>
    <description>Overall survival assessed at 6 months since diagnosis of progression on first-line therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Responses as Determined by RECIST Criteria Using CT or Magnetic Resonance Imaging (MRI) Assessment</measure>
    <time_frame>2 years</time_frame>
    <description>Tumor response rate as determined by RECIST criteria using CT or Magnetic Resonance Imaging (MRI) assessment of tumor size every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 years</time_frame>
    <description>Number of adverse events by grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60 Day All-cause Mortality Rate</measure>
    <time_frame>60 days</time_frame>
    <description>Number of Participants with 60 Day All-cause Mortality</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Yttrium-90 Radioactive Resin Microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yttrium-90 Radioactive Resin Microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Yttrium-90 Radioactive Resin Microspheres</intervention_name>
    <description>An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
    <arm_group_label>Yttrium-90 Radioactive Resin Microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed colorectal carcinoma. Liver metastasis will be confirmed by&#xD;
             either PET scan or biopsy.&#xD;
&#xD;
          -  Ability to understand and willingness to sign written informed consent&#xD;
&#xD;
          -  Minimum of 18 years of age&#xD;
&#xD;
          -  Liver dominant metastases measurable by CT or MRI and therefore amenable to serial&#xD;
             assessment using RECIST criteria&#xD;
&#xD;
          -  Progressive disease of metastatic colorectal carcinoma on first line combination&#xD;
             chemotherapy with a 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) based regimen&#xD;
             (Folinic Acid, Oxaliplatin and Fluorouracil)or failure of first line chemotherapy due&#xD;
             to toxicity&#xD;
&#xD;
          -  Candidate for second line chemotherapy with a fluorouracil, leucovorin, and irinotecan&#xD;
             (FOLFIRI) regimen. Per standard of care, second line chemotherapy will not include&#xD;
             Bevacizumab.&#xD;
&#xD;
          -  Karnofsky Performance Score (KPS) of 70% or greater&#xD;
&#xD;
          -  Life expectancy of greater than or equal to four months by investigator estimation&#xD;
&#xD;
          -  Females with negative urine or serum pregnancy test&#xD;
&#xD;
          -  Effective double barrier contraception for a minimum of two months following the final&#xD;
             infusion of microspheres&#xD;
&#xD;
          -  Patients who are not candidates for transarterial chemoembolization (TACE), thermal&#xD;
             ablation or surgical resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dominant extra-hepatic disease including cerebral metastases or other extra-hepatic&#xD;
             metastases that are symptomatic&#xD;
&#xD;
          -  Large volume ascites assessed by cross sectional CT imaging&#xD;
&#xD;
          -  Any chemotherapy &lt; 4 weeks prior to the first microsphere treatment&#xD;
&#xD;
          -  Anticipated to need Avastin chemotherapy within eight weeks of day M1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1.5 x 109/L&#xD;
&#xD;
          -  Platelets (PLT) &lt; 60,000/mm3&#xD;
&#xD;
          -  Hemoglobin (Hgb) &lt; 9.0 gm/dL&#xD;
&#xD;
          -  Prothrombin time (PT) or Partial Prothrombin time (PTT) &gt; upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Forced expiratory volume (FEV1) &lt; 1L by baseline pulmonary function tests (ordered if&#xD;
             investigator judges it to be clinically indicated)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 5 times upper&#xD;
             limits of normal (ULN) or total bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
          -  History of incompetent sphincter of oddi (e.g.: sphincterotomy, biliary-enteric&#xD;
             anastamosis, or percutaneous biliary drain)&#xD;
&#xD;
          -  Severe hypoalbuminemia (albumin &lt; 2.0 g/dL)&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 2.5 times ULN&#xD;
&#xD;
          -  Greater than 20% lung shunting (determined by the MAA - Tc 99 nuclear medicine lung&#xD;
             shunt scan)&#xD;
&#xD;
          -  Pre assessment angiogram and MAA scan demonstrating any uncorrectable activity in the&#xD;
             stomach, bowel or pancreas&#xD;
&#xD;
          -  Major surgery &lt; 4 weeks prior to the first microsphere treatment&#xD;
&#xD;
          -  Female who is pregnant or nursing&#xD;
&#xD;
          -  Men and women of childbearing potential wishing to conceive &lt; 2 months following the&#xD;
             completion of the microsphere portion of the study.&#xD;
&#xD;
          -  Any investigational agent administered &lt; 4 weeks prior to microsphere treatment&#xD;
&#xD;
          -  A known history of hepatitis B or hepatitis C&#xD;
&#xD;
          -  Known hypersensitivity to any component of microsphere infusion&#xD;
&#xD;
          -  History of, or current coagulation or bleeding disorder&#xD;
&#xD;
          -  History of significant hepatic cirrhosis, fibrosis or hemochromatosis&#xD;
&#xD;
          -  History of malignancy, other than colorectal cancer, within five years of the start of&#xD;
             study participation, except in situ cervical or skin cancer&#xD;
&#xD;
          -  Active severe infection or any other concurrent disease or medical conditions that are&#xD;
             likely to interfere with the study as judged by the investigator&#xD;
&#xD;
          -  Prior treatment with radioactive microspheres or external beam radiation therapy to&#xD;
             the liver&#xD;
&#xD;
          -  Prophylactic anticoagulation and nonsteroidal antiplatelet drugs are only a&#xD;
             contraindication, if the PT/PTT are above the ULN. Plavix (clopidogrel) will need to&#xD;
             be stopped 5 days prior to the hepatic-angiogram and the microsphere procedures, then&#xD;
             started the next day.&#xD;
&#xD;
          -  History of right to left, bi-directional or transient right to left cardiac shunts,&#xD;
             worsening or clinically unstable congestive heart failure, acute myocardial infarction&#xD;
             or acute coronary syndromes serious ventricular arrhythmias or high risk for&#xD;
             arrhythmias due to prolongation of the QT interval, respiratory failure as manifested&#xD;
             by signs or symptoms of carbon dioxide retention or hypoxemia or severe emphysema,&#xD;
             pulmonary emboli or other conditions that causes pulmonary hypertension due to&#xD;
             compromised pulmonary arterial vasculature&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Reid, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Tony Reid, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>colorectal</keyword>
  <keyword>metastasis</keyword>
  <keyword>carcinoma</keyword>
  <keyword>Yttrium-90</keyword>
  <keyword>microspheres</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Yttrium-90 Radioactive Resin Microspheres</title>
          <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Yttrium-90 Radioactive Resin Microspheres</title>
          <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" lower_limit="52" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>United States California</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PFS</title>
        <description>Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s)</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium-90 Radioactive Resin Microspheres</title>
            <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS</title>
          <description>Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s)</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Overall Survival at 6 Months</title>
        <description>Overall survival assessed at 6 months since diagnosis of progression on first-line therapy</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium-90 Radioactive Resin Microspheres</title>
            <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Overall Survival at 6 Months</title>
          <description>Overall survival assessed at 6 months since diagnosis of progression on first-line therapy</description>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Responses as Determined by RECIST Criteria Using CT or Magnetic Resonance Imaging (MRI) Assessment</title>
        <description>Tumor response rate as determined by RECIST criteria using CT or Magnetic Resonance Imaging (MRI) assessment of tumor size every 3 months</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium-90 Radioactive Resin Microspheres</title>
            <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Responses as Determined by RECIST Criteria Using CT or Magnetic Resonance Imaging (MRI) Assessment</title>
          <description>Tumor response rate as determined by RECIST criteria using CT or Magnetic Resonance Imaging (MRI) assessment of tumor size every 3 months</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number of adverse events by grade</description>
        <time_frame>1 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium-90 Radioactive Resin Microspheres</title>
            <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of adverse events by grade</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alk Phos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>60 Day All-cause Mortality Rate</title>
        <description>Number of Participants with 60 Day All-cause Mortality</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Yttrium-90 Radioactive Resin Microspheres</title>
            <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>60 Day All-cause Mortality Rate</title>
          <description>Number of Participants with 60 Day All-cause Mortality</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Yttrium-90 Radioactive Resin Microspheres</title>
          <description>Yttrium-90 Radioactive Resin Microspheres&#xD;
Yttrium-90 Radioactive Resin Microspheres: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alk Phos</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tony Reid</name_or_title>
      <organization>UC San Diego</organization>
      <phone>8583531942</phone>
      <email>treid@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

